Compare iShares Bitcoin Trust (IBIT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Summit Therapeutics Inc — how do they compare? iShares Bitcoin Trust trades at $46.55 (market cap $67.31B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: iShares Bitcoin Trust is far larger — about 4.9× Summit Therapeutics Inc's market cap, and iShares Bitcoin Trust is more actively traded (56,154,544 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Summit Therapeutics Inc for 16 Days on average.
| IBIT | SMMT | |
|---|---|---|
Market Cap | $67.31B | $13.71B |
Volume | 56,154,544 | 6,173,057 |
Sector | Crypto-linked | Health |
52-Week High | $66.20 | $26.38 |
52-Week Low | $33.29 | $12.43 |
Typical Hold Time | 40 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $46.26, down 2.01% today amid bearish technical signals. The stock faces resistance at $47-$48 with support at $44-$46. Recent news highlights significant institutional inflows, including a $196 million single-day inflow on October 1, 2026, reflecting renewed investor confidence despite current price weakness.
The outlook remains cautious with technical indicators showing bearish momentum, though strong institutional interest suggests potential recovery. Key risks include market volatility and ETF fee structures, while analyst sentiment appears mixed with ongoing monitoring of Bitcoin market dynamics influencing stock performance.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
